XLO news & sentiment — Xilio Therapeutics, Inc.

APR 16·Stock TitanMed

Xilio brings in a 30-year biotech veteran as board member

Xilio Therapeutics (Nasdaq: XLO) has appointed Cheryl R. Blanchard, Ph.D., a biotech veteran with over 30 years of experience, to its board of directors, effective April 16, 2026. Dr. Blanchard's expertise in biologics, devices, and commercial strategy, including her current role as executive chair of Anika, is expected to support Xilio's masked immuno-oncology pipeline. This appointment follows the departure of Christina Rossi from the board on April 15, 2026.

NOV 7·GlobeNewswire

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer ( SITC ) 40th Annual Meeting

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden ...

NOV 7·GlobeNewswire

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer ( SITC ) 40th Annual Meeting

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index ...

$XLO

Xilio brings in a 30-year biotech veteran as board member

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer ( SITC ) 40th Annual Meeting

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer ( SITC ) 40th Annual Meeting

News on $XLO